HOME ·

01477.HK

OCUMENSION-B (01477.HK): NDA for OT-301 in Open-Angle Glaucoma or Ocular Hypertension Accepted by NMPA
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-11
OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China
Tags：
OCUMENSION-B01477.HKR&D Progress
2026-09-02
CUMENSION-B (01477.HK): First Patient Dosed in Phase III Clinical Trial of OT-202 for Dry Eye Disease
Tags：
CUMENSION-B01477.HKR&D Progress
2026-08-31
Ocuvitas Therapeutics(01477.HK): Chief Financial Officer Yuen Tim Si Resigns; Chen Tingchan Appointed Sole Company Secretary and Authorised Representative
Tags：
Ocuvitas Therapeutics01477.HK
2026-07-01
OCUMENSION-B(01477.HK): First Patient Enrolled in Phase III Clinical Trial of OT-802 (Pilocarpine Hydrochloride Eye Drops)
Tags：
OCUMENSION-B01477.HKFirst patient enrollment
2026-05-28